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Seasonal malaria chemoprevention (SMC) has shown high protective efficacy against clini-
cal malaria and severe malaria in a series of clinical trials. We evaluated the effectiveness of
SMC treatments against clinical malaria when delivered at scale through national malaria
control programmes in 2015 and 2016.
Methods and findings
Case–control studies were carried out in Mali and The Gambia in 2015, and in Burkina
Faso, Chad, Mali, Nigeria, and The Gambia in 2016. Children aged 3–59 months presenting
at selected health facilities with microscopically confirmed clinical malaria were recruited as
cases. Two controls per case were recruited concurrently (on or shortly after the day the
case was detected) from the neighbourhood in which the case lived. The primary exposure
was the time since the most recent course of SMC treatment, determined from SMC recipi-
ent cards, caregiver recall, and administrative records. Conditional logistic regression was
used to estimate the odds ratio (OR) associated with receipt of SMC within the previous 28
days, and SMC 29 to 42 days ago, compared with no SMC in the past 42 days. These ORs,
which are equivalent to incidence rate ratios, were used to calculate the percentage reduc-
tion in clinical malaria incidence in the corresponding time periods. Results from individual
countries were pooled in a random-effects meta-analysis. In total, 2,126 cases and 4,252
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controls were included in the analysis. Across the 7 studies, the mean age ranged from 1.7
to 2.4 years and from 2.1 to 2.8 years among controls and cases, respectively; 42.2%–
50.9% and 38.9%–46.9% of controls and cases, respectively, were male. In all 7 individual
case–control studies, a high degree of personal protection from SMC against clinical malaria
was observed, ranging from 73% in Mali in 2016 to 98% in Mali in 2015. The overall OR for
SMC within 28 days was 0.12 (95% CI: 0.06, 0.21; p < 0.001), indicating a protective effec-
tiveness of 88% (95% CI: 79%, 94%). Effectiveness against clinical malaria for SMC 29–42
days ago was 61% (95% CI: 47%, 72%). Similar results were obtained when the analysis
was restricted to cases with parasite density in excess of 5,000 parasites per microlitre: Pro-
tective effectiveness 90% (95% CI: 79%, 96%; P<0.001), and 59% (95% CI: 34%, 74%;
P<0.001) for SMC 0–28 days and 29–42 days ago, respectively. Potential limitations include
the possibility of residual confounding due to an association between exposure to malaria
and access to SMC, or differences in access to SMC between patients attending a clinic
and community controls; however, neighbourhood matching of cases and controls, and
covariate adjustment, attempted to control for these aspects, and the observed decline in
protection over time, consistent with expected trends, argues against a major bias from
these sources.
Conclusions
SMC administered as part of routine national malaria control activities provided a very high
level of personal protection against clinical malaria over 28 days post-treatment, similar to
the efficacy observed in clinical trials. The case–control design used in this study can be
used at intervals to ensure SMC treatments remain effective.
Author summary
Why was this study done?
• Seasonal malaria chemoprevention (SMC) consists of monthly administration of 2 anti-
malarial drugs, sulphadoxine–pyrimethamine and amodiaquine, to children 3–59
months of age during the peak months of malaria transmission.
• SMC provided a high level of protection against clinical malaria in clinical trials, and
has been recommended by the World Health Organization since 2012 for areas of the
Sahel and sub-Sahel regions of Africa with seasonal transmission. This study was done
to determine whether the efficacy observed in the trials translated into effectiveness
when SMC was deployed at scale.
What did the researchers do and find?
• The researchers carried out case–control studies in Burkina Faso, Chad, Mali, Nigeria,
and The Gambia to estimate the protective effectiveness of SMC treatments against clin-
ical malaria.
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• Cases were children with confirmed malaria at a health facility. For each case, 2 controls
were chosen from the neighbourhood where the case lived. Dates of SMC treatments
were determined from SMC record cards and by asking caregivers. The effectiveness of
monthly SMC treatment in preventing clinical malaria was estimated by comparison of
when cases and controls had most recently received SMC.
• In all 7 case–control studies (2 in 2015 and 5 in 2016), SMC provided a high level of pro-
tection against clinical malaria. Protection was highest in the first 4 weeks after treat-
ment. Pooling estimates across the 7 studies, clinical malaria incidence during the first 4
weeks after SMC treatment was reduced on average by 88%. Protection from SMC was
lower in the period 5–6 weeks post-administration.
What do these findings mean?
• SMC was highly effective in preventing clinical malaria when delivered at scale through
national malaria control programmes, with protection comparable to that observed dur-
ing clinical trials. This case–control design can be used by national malaria control pro-
grammes at intervals to confirm that SMC remains effective.
Introduction
Seasonal malaria chemoprevention (SMC) is a relatively new tool for the prevention of malaria
in areas with seasonal transmission. SMC consists of monthly administration of a full thera-
peutic course of the antimalarials sulphadoxine–pyrimethamine (SP) and amodiaquine (AQ)
during the peak malaria season, and has been shown to provide a high level of protection
against malaria in a series of clinical trials [1]. Since being recommended by the World Health
Organization in 2012 [2], SMC has been introduced as part of national malaria control strate-
gies in countries of the Sahel and sub-Sahel regions of West Africa, and reached 22 million
children in 13 countries in 2019 [3].
With SMC deployed at scale, there is a need to confirm if the high level of protection against
clinical malaria observed in clinical trials is replicated in a programmatic field setting, as a
number of factors (such as drug quality, poor administration, poor adherence to the 3-day reg-
imen, and the presence of illnesses that affect drug absorption) could limit treatment efficacy
in practice if SMC delivery is not well supervised. There is also an ongoing need to monitor
SMC effectiveness, which could decline over time if parasites become more resistant to SP or
AQ, or both, in regions where SMC is being used. Prior to widespread implementation of
SMC, the frequencies of molecular markers of resistance to both SP and AQ were low in coun-
tries that now have SMC programmes [4], but this situation could change. Since the relation-
ship between marker prevalence and the protective efficacy (PE) of chemoprevention is not
straightforward [5,6], monitoring the prevalence of these molecular markers alone will not be
sufficient to understand the potential impact of changing drug resistance patterns on SMC effi-
cacy, and epidemiological studies of effects on malaria incidence are needed. Other studies
have measured the impact of SMC on prevalence of asymptomatic Plasmodium falciparum
infection and the prevalence of fever [7–9], but the effectiveness of SMC in protecting children
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against clinical malaria requiring treatment at a health facility is the key knowledge gap, since
this measure would be more easily interpreted.
Case–control studies are logistically less complex than cohort studies and are commonly
used to estimate the protective effectiveness of vaccines post-implementation [10]. Case–con-
trol studies have also been used to evaluate other preventive interventions for malaria, such as
treated bednets [11,12]. As usually designed, with controls recruited concurrently as cases
occur, case–control studies provide an estimate of the incidence rate ratio for the exposure
[13,14], and hence the protective effectiveness, i.e., the percentage reduction in disease inci-
dence associated with the exposure, calculated as 100 × (1 − rate ratio). However, case–control
studies need to be planned carefully in order to ensure that receipt of the intervention (the
exposure) is accurately measured, and that the controls represent the population that produced
the cases.
The ACCESS-SMC project evaluated the impact and effectiveness of SMC delivered in 7
countries of the sub-Sahel region of Africa during 2015 and 2016 [4]. Although delivery meth-
ods varied between countries (some countries delivered SMC door-to-door, and others at
fixed points in the community), procedures when a recipient child was contacted were stan-
dardised, and the same regimen (a single treatment with SP plus AQ daily for 3 days) was
used. In this paper, we report the results of case–control studies undertaken in 5 of these coun-
tries—Burkina Faso, Chad, Mali, Nigeria, and The Gambia—to estimate the protective effec-
tiveness of SMC against clinical malaria across the region where it has been deployed.
Methods
The outcome of interest in this study was clinical malaria, i.e., children seeking care for fever
due to P. falciparum infection confirmed by blood smear. In 2015, case–control studies were
conducted in Mali and The Gambia during the late rainy season and early dry season (Fig 1A),
from October to December 2015 in Mali, and December 2015 to January 2016 in The Gambia.
In Mali, cases were recruited at Diema and Sanso health centres, and in The Gambia, at Basse,
Koina, Fatoto, Sabi, Gambissara, and Jahali health centres and Bansang Hospital, which serves
the surrounding rural area.
In 2016, cases were recruited in 5 countries (Burkina Faso, Chad, Mali, Nigeria, and The
Gambia) over the entire transmission season (i.e., starting from the time of the first SMC
cycle) and were recruited until approximately 8 weeks after the final SMC cycle (Fig 1B), to
allow protection to be estimated beyond the first month after treatment. Specific dates were as
follows: Burkina Faso, August 2016 to January 2017; Chad, August 2016 to March 2017; Mali,
August 2016 to January 2017; Nigeria, August 2016 to February 2017; The Gambia, September
to December 2016. To meet the overall target sample size and to ensure that cases were
recruited uniformly during the transmission period, and with respect to the timing of monthly
SMC cycles, study teams recruited an approximate quota of cases each week (S1 Methods). In
Mali and The Gambia, the same health centres were used in 2016 as in 2015, except that Ban-
sang Hospital was not used. Cases were recruited in 2 health centres in Burkina Faso (Zitenga
and Koupela), 4 health centres in Chad (1 in Koundoul and 3 in N’Djamena), and in the out-
patient department of general hospitals in Nigeria (Gwadabawa and Wurno in Sokoto State;
Kaura Namoda and Tsafe in Zamfara State). Apart from the 3 health centres in N’Djamena,
which served a partly urban area, all clinics included in the study served a rural area.
Recruitment of clinical malaria cases
Children aged 3–59 months presenting at health facilities with fever (axillary
temperature� 37.5˚C or a history of fever in the last 48 hours) who did not have respiratory
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infection or other obvious cause of the fever were tested for the presence of malaria infection
using microscopy. Microscopic examination of blood smears was used to reduce the detection
of false positives that is common with rapid diagnostic tests [15]. After administering treat-
ment, children with confirmed clinical malaria who were accompanied by a parent or legal
guardian able to provide consent were invited to participate. Signed consent was sought from
the caregiver after explaining the aims and procedures of the study, and the child enrolled as a
case. A field worker visited the child’s home as soon as possible thereafter (usually later the
same day or the next day). At the home visit, the dates of SMC treatments the case had received
were determined by inspecting the child’s SMC card, if available, and by asking the caregiver
Fig 1. Schematic of recruitment of cases and controls in 2015 and 2016. (a) 2015; (b) 2016. This schematic of
recruitment shows the timing of seasonal malaria chemoprevention (SMC) cycles (red arrows) and the recruitment
period of the case–control study (black dots) in relation to the typical seasonal peak in malaria cases (hypothetical
seasonality pattern shown by the blue line). In 2015, cases and corresponding controls were recruited in the late rainy
season and early dry season in Mali and The Gambia. In 2016, cases and controls were recruited uniformly across the
entire malaria transmission season in Burkina Faso, Chad, Mali, Nigeria, and The Gambia, from the time of the first
SMC cycle until 8 weeks after the final cycle.
https://doi.org/10.1371/journal.pmed.1003727.g001
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to recall when the child was last treated. If there was a disagreement between the caregiver’s
recollection and the card record, interviewers attempted to verify the treatment date by check-
ing against the known dates of SMC delivery in the village and by asking other family mem-
bers. Information was also collected to allow adjustment for the following potential
confounding factors: age, sex, whether the child slept under a bednet the previous night, the
type of net (determined by inspecting the sleeping space and the net), and caregiver’s educa-
tion and socioeconomic status (SES, calculated separately for each study using principal com-
ponent analysis of durable assets and amenities of the household). Information was also
collected on the number of children aged 3–59 months in the household and, in 2016 only,
prior antimalarial treatment (other than SMC) in the past 3 weeks, although these factors were
found not to be important confounders and were not adjusted for.
Recruitment of controls
Controls were selected from the same neighbourhood as the case (i.e., matched on neighbour-
hood) in order to control for potential confounding by level of exposure to malaria transmis-
sion and access to healthcare. After interviewing the case, compounds in the neighbourhood
of the case were visited to recruit 2 controls from separate households. Households were vis-
ited starting at least 3 compounds away from the home of the malaria case. If there was more
than 1 eligible child in a household, a Kish grid was used to select one [16]. All children aged
3–59 months were eligible as controls, including unwell children who might have had malaria
(such children were then either treated or referred to health facilities for treatment). Interview-
ers were trained to record each household that was approached and each child invited to par-
ticipate using a specific form, in order to confirm participation rates among potential controls.
This was done in both years, on paper forms in 2015 (separate from the study forms on a tablet
personal computer [PC]) and directly on tablet PCs in 2016. Details about SMC treatments
and potential confounders for controls were collected in the same way as for cases. Interviews
were timed to check that a similar length of time was spent collecting information from cases
and controls.
Primary exposure
The primary exposure was defined for cases and controls as the time since the first daily dose
of the most recent SMC treatment, up to the time the case was diagnosed, i.e., ignoring any
SMC treatment courses that were administered between recruitment of the case and recruit-
ment of the control (Fig 2). This exposure was categorised as SMC within the previous 28 days,
SMC 29–42 days ago, and no SMC within the past 42 days; these groupings were chosen
because the PE from SMC against clinical malaria has been shown to be very high in the initial
4 weeks after administration, with protection then waning over the period between 4 and 6
weeks [17].
Laboratory methods and quality control
Thick blood films were stained with Giemsa and air-dried, with 100 high-power fields read
before declaring a slide negative. Parasite densities were estimated by counting against 200
white blood cells (WBCs) and assuming 8,000 WBCs per microlitre. In Nigeria, parasite den-
sity was categorised, and the exact density was not recorded. All slides were double read, with
discrepancies on result or density resolved either by a third reader or, in Burkina Faso, with
the expert reader rereading their slide.
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Monitoring of study activities and data management
Monitors from London School of Hygiene & Tropical Medicine and from Universite Cheikh
Anta Diop in Dakar, Senegal, visited each site to check that the study protocol was being fol-
lowed. In both years, data were collected on tablet PCs (Google Nexus) using the iFormBuilder
platform, uploaded to a server, and imported to a Microsoft Access database, except in Nigeria
(where data were collected using paper forms and then double entered into an Access database;
for quality control a sample of forms were scanned and checked against the dataset). Date and
other data consistency checks were carried out on the central database, with queries resolved
by the teams in each centre.
Statistical methods
All analyses were conducted in Stata 15 (StataCorp, College Station, Texas).
Protective effectiveness of SMC. The SMC status of cases and controls within matched
sets was examined by tabulation. Only case–control sets where the case and at least 1 control
were discordant for exposure contribute to the matched analysis. The timing of the most
recent SMC course for cases and controls was therefore plotted within discordant case–control
sets: If cases tended to have received SMC longer ago than controls, this indicates that SMC is
protective. Conditional logistic regression was then used to estimate crude and adjusted (for
age, sex, long-lasting insecticidal net [LLIN] use, education, and SES) odds ratios (ORs) for
SMC 0–28 days and 29–42 days ago, relative to children with no SMC within the past 42 days
(reference group). All models were adjusted for all of the above confounders (i.e., no variable
selection), with the exception of the Mali 2015 and The Gambia 2015 studies, in which child’s
Fig 2. Calculation of exposure in controls with respect to the date that the case was diagnosed. For cases, the
primary exposure (time since the most recent seasonal malaria chemoprevention [SMC] course) was defined on the
basis of the most recent SMC cycle received at the time of diagnosis. For controls, the primary exposure was defined on
the basis of the most recent SMC received at the time the case was diagnosed. On most occasions, this was
straightforward, as for both case and control, the most recent SMC cycle was some time ago, and defining the exposure
relied only on accurate recording of dates. However, in a few instances, the case was recruited just before a new SMC
cycle was delivered, and the control was not recruited until just afterwards. The figure shows the example of a case
being recruited just before SMC 3, and a control being recruited just after SMC 3. Because the exposure for the control
is defined based on the most recent SMC received at the time the case is diagnosed, in this example the control’s
exposure is based on SMC 2, rather than SMC 3. This avoids the possible bias of some controls appearing to have
received SMC much more recently than cases (which would inflate the apparent benefit of SMC) as an artefact of the
slight delay in the recruitment of controls.
https://doi.org/10.1371/journal.pmed.1003727.g002
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sex and SES, respectively, were not captured for all children, so these were not included in the
adjusted model.
As described above, due to the concurrent recruitment of controls, the OR can be inter-
preted as the incidence rate ratio. The protective effectiveness of SMC in the given time peri-
ods against clinical malaria was calculated as 1 − OR, expressed as a percentage. Although we
did not expect the effectiveness of SMC to vary according to the length of the malaria transmis-
sion season, the study centres in Mali were in parts of the country with markedly different
malaria epidemiology (Diema in the Sahelian region, 200 km north of Bamako; Sanso is
approximately 400 km south of Diema), so we prespecified an analysis examining evidence for
effect modification (interaction) of SMC effectiveness by study area, using the likelihood ratio
test (LRT) to compare models with and without an interaction term between the SMC variable
and site. Other countries were treated as a single centre. A multivariable regression model was
also used to estimate the protective effectiveness of LLIN use the night before the case or con-
trol was interviewed.
Meta-analysis. To obtain a summary estimate of SMC protection between 0 and 28 days,
and between 29 and 42 days, a random-effects meta-analysis was conducted using the log OR
and its standard error from each of the 7 studies. The contribution of each study to the overall
estimate and evidence for heterogeneity in the OR was estimated.
High-parasite-density malaria. As a secondary analysis, to increase the probability that
the observed illness is attributable to P. falciparum infection (rather than another cause, with
coincidental parasitaemia), the analysis described above was repeated restricted to cases with
parasite density greater than 5,000 per microlitre, and their corresponding controls. This anal-
ysis excluded Nigeria, 2016, as the exact density was not available. As for children with parasi-
taemia of any density, results were combined in a random-effects meta-analysis as described
above.
All analyses were planned before the final database was locked for analyses. However,
in response to comments from the statistical peer reviewer, we subsequently carried out a
fixed-effects meta-analysis to compare with the random-effects model, and calculated the pre-
diction interval for the random-effects meta-analysis. This study is reported as per the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
(S1 STROBE Checklist).
Ethics
The protocol was approved by the London School of Hygiene & Tropical Medicine Research
Ethics Committee (No. 9944, 11 August 2015) and by ethics committees in each participating
country. Signed consent was obtained from caregivers for participation in the case–control
studies after explaining the study aims and procedures using a standard script.
Results
Characteristics of cases and controls
Across the 7 studies in the 5 countries (2 in 2015 and 5 in 2016), there were generally more
females than males among both controls and cases (42.2%–50.9% and 38.9%–46.9% of controls
and cases, respectively, were male). Mean age was slightly lower among the controls compared
to the cases (mean age for controls ranged from 1.7 years to 2.4 years, and mean age for cases
from 2.1 to 2.8 years) (Table 1). LLIN use among cases and controls the night before the inter-
view was high in most studies, ranging from 84.6% in Nigeria, 2016, to 97.5% in Burkina Faso,
2016. The exception was Chad, 2016, in which use of LLIN was only 38.6%. Mothers/caregivers
of cases generally had a slightly lower education level than mothers/caregivers of controls. The
PLOS MEDICINE Case-control studies to evaluate seasonal malaria chemoprevention at scale
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distribution of education status and SES categories among the cases and controls is also shown
in Table 1. Refusals to participate among controls were not systematically documented on tab-
let PCs in 2015, but were reported to be very rare. In 2016, there were no refusals in Burkina
Faso and Nigeria, 1 each in Chad and Mali, and 5 in The Gambia.
In all studies, the majority of controls were recruited within 2 days of the case attending the
health facility. In 5 studies, all controls were recruited within 7 days. In Burkina Faso and
Chad, in 2016, some controls were recruited between 7 and 30 days after the case, but the
recording and analysis focused on the status of the controls at the time the case attended the
health facility (Table A in S1 Tables). Availability of the SMC card for inspection at the home
visit among the controls ranged from 34.0% in Mali, 2016, to 99.4% in Burkina Faso, 2016
(Table B in S1 Tables). Availability of the card was generally lower among cases (as would be
expected, as children who have not received SMC would not have a recipient card).
Parasite density among the clinical malaria cases recruited for the study was generally high:
The percentage of cases with parasite density greater than 5,000 parasites per microlitre ranged
from 65.8% in Chad, 2016, to 83.3% in Mali, 2016 (Table C in S1 Tables). Geometric mean par-
asite density per microlitre ranged from 9,475 in the Gambia, 2016, to 24,191 in Mali, 2016.
According to caregiver reports, all 3 daily doses of SMC were administered to a very high per-
centage of children in all of the studies (Table D in S1 Tables). Among controls who had
received SMC, the percentage reported to have successfully swallowed all 3 daily doses ranged
from 61.8% in The Gambia, 2015, to 97.1% in Burkina Faso, 2016. Caregiver-reported spitting
or vomiting of at least 1 of the daily doses was variable (ranging from 2.4% in Burkina Faso,
2016, to 34.6% in The Gambia, 2015). Very few doses were missed because the child refused to
take the medication (0.11% in Burkina Faso, 2016, to 5.8% in Nigeria, 2016).
The most common discrepancy between cases and controls in the primary exposure (time
since SMC) was the case having not received SMC in the past 28 days, while at least 1 of the
controls had received SMC in this period (Table E in S1 Tables). Cases generally had SMC lon-
ger ago than controls (Fig A in S1 Fig). Both these findings are consistent with a protective
effect of SMC against clinical malaria.
Protective effectiveness of SMC against clinical malaria by country
In 2015, 252 cases and 504 controls were recruited in Mali; 111 case–control sets were discor-
dant for recent SMC and contributed to the analysis (Table E in S1 Tables). There were very
few instances where a case, but neither control, had received SMC within the previous 28 days,
leading to a very high estimate of protection from SMC in the first 28 days. There were missing
data on the most recent SMC for 96 controls and 32 cases, arising from imprecise recording or
recall of dates in Mali in 2015. After adjustment for age, LLIN use, SES, and education, the
adjusted OR for SMC within the previous 28 days was 0.02 (95% CI: 0.01, 0.06), indicating pro-
tective effectiveness against clinical malaria of 98% (95% CI: 94%, 99.5%) (Table 2). There was
no evidence of protection beyond this period, nor of heterogeneity between Diema and Sanso
districts (LRT p = 0.78). In 2015, 226 case–control sets were recruited in The Gambia, 51 of
which were discordant for SMC (Table E in S1 Tables). After adjustment for sex, age, LLIN
use, and education, the adjusted OR for SMC 0–28 days ago was 0.15 (95% CI: 0.04, 0.56) and
for SMC 29–42 days ago was 0.23 (95% CI: 0.10, 0.53), indicating a protective effectiveness of
85.0% (95% CI: 43.1%, 96.0%) and 77.2% (95% CI: 47.3%, 90.2%), respectively, in these 2 peri-
ods (Table 2).
In 2016, the following numbers of case–control sets were recruited: 459 in Burkina Faso,
199 in Chad, 341 in Mali, 460 in Nigeria, and 248 in The Gambia. In Nigeria, 59 controls had
dates of SMC recorded that were logically impossible (later than the date of recruitment),
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suggesting either issues with recording on the SMC card itself or with transcription onto the
paper form; the 59 affected sets were discarded, leaving 401 case–control sets in the dataset.
The number of discordant sets in which exposure differed between the case and controls was
95, 63, 194, 117, and 103, respectively, in Burkina Faso, Chad, Mali, Nigeria, and The Gambia
(Table E in S1 Tables). After adjustment for age, sex, LLIN use, SES, and education, ORs for
SMC within the previous 28 days ranged from 0.07 (95% CI: 0.03, 0.17) in Burkina Faso to
0.27 (95% CI: 0.18, 0.42) in Mali, indicating a range of protective effectiveness estimates
between 72.9% and 93.4%. The OR and PE for SMC within 28 days by country were as follows:
Burkina Faso, OR 0.07 (95% CI: 0.03, 0.17), PE 93.4% (95% CI: 83.1%, 97.4%); Chad, OR 0.22
(95% CI: 0.11, 0.47), PE 77.8% (95% CI: 53.1%, 89.5%); Mali, OR 0.27 (95% CI: 0.18, 0.42), PE
72.9% (95% CI: 58.5%, 82.3%); Nigeria, OR 0.17 (95% CI: 0.09, 0.31), PE 83.1% (95% CI:
69.1%, 90.8%); and The Gambia, OR 0.08 (95% CI: 0.04, 0.17), PE 91.9% (95% CI: 83.0%,
96.1%).
Protective effectiveness in the period 29–42 days ranged from 46.3% (95% CI: 8.2%, 68.6%)
in Mali, to 77.9% (95% CI: 46.6%, 90.8%) in the Gambia (Table 2). PE in each country was as
follows: Burkina Faso, 57.2% (95% CI: −14.4%, 84.0%); Chad, 56.6% (95% CI: −25.6%, 85.0%);
Table 2. Association of SMC with clinical malaria in individual studies.
Study SMC Crude OR 95% CI Adjusted OR 95% CI p-Value PE 95% CI
Mali, 2015 Within previous 28 days 0.022 0.007, 0.070 0.017 0.005, 0.059 <0.001 98.3 94.1, 99.5
29–42 days ago 0.473 0.171, 1.308 0.482 0.162, 1.432 0.189 51.8 −43.2, 83.8
43+ days ago — — — — — — —
The Gambia, 2015 Within previous 28 days 0.131 0.035, 0.487 0.150 0.040, 0.569 0.005 85.0 43.1, 96.0
29–42 days ago 0.207 0.092, 0.467 0.228 0.098, 0.527 0.001 77.2 47.3, 90.2
43+ days ago — — — — — — —
Burkina Faso, 2016 Within previous 28 days 0.047 0.020, 0.113 0.066 0.026, 0.169 <0.001 93.4 83.1, 97.4
29–42 days ago 0.310 0.129, 0.743 0.428 0.160, 1.144 0.091 57.2 −14.4, 84.0
43+ days ago — — — — — — —
Chad, 2016 Within previous 28 days 0.317 0.163, 0.618 0.222 0.105, 0.469 <0.001 77.8 53.1, 89.5
29–42 days ago 0.442 0.169, 1.161 0.434 0.150, 1.256 0.124 56.6 −25.6, 85.0
43+ days ago — — — — — — —
Mali, 2016 Within previous 28 days 0.294 0.201, 0.431 0.271 0.177, 0.415 <0.001 72.9 58.5, 82.3
29–42 days ago 0.637 0.389, 1.042 0.537 0.314, 0.918 0.023 46.3 8.2, 68.6
43+ days ago — — — — — — —
Nigeria, 2016 Within previous 28 days 0.218 0.132, 0.360 0.169 0.092, 0.309 <0.001 83.1 69.1, 90.8
29–42 days ago 0.410 0.198, 0.848 0.363 0.151, 0.873 0.024 63.7 12.7, 84.9
43+ days ago — — — — — — —
The Gambia, 2016 Within previous 28 days 0.081 0.041, 0.159 0.081 0.039, 0.170 <0.001 91.9 83.0, 96.1
29–42 days ago 0.267 0.121, 0.588 0.221 0.092, 0.534 0.001 77.9 46.6, 90.8
43+ days ago — — — — — — —
Results are adjusted for age, sex, use of a long-lasting insecticidal net, socioeconomic status, and caregiver’s education, apart from Mali, 2015, where sex was not
collected, and The Gambia, 2015, which is not adjusted for socioeconomic status, as this was missing for 162 records but was not an important confounder. Data on
recent (non-SMC) antimalarial treatment was collected in 2016. In 3 countries recent antimalarial treatment was relatively rarely reported (6 times in The Gambia, 2016,
and 34 times each in Burkina Faso, 2016, and Mali, 2016), and adjusting for recent treatment made very little difference to model estimates. In Chad, 2016, recent
treatment with an antimalarial was commonly reported (17.1% of controls and 29.6% of cases). Adjustment for this in addition to the other covariates resulted in an
estimate of PE of 73.4% (95% CI: 40.4%, 88.2%) in the first 28 days and 49.5% (95% CI: −47.7%, +82.7%) for the period 29–42 days. In Nigeria, 2016, recent treatment
was reported by 3.74% of controls and 15.2% of cases, but adjusting for recent treatment made very little change to the estimates of PE: 81.2% (95% CI: 64.8%, 90.0%) in
the first 28 days and 66.9% (95% CI: 17.2%, 86.8%) for the period 29–42 days. OR, odds ratio; PE, protective efficacy; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1003727.t002
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Mali, 46.3% (95% CI: 8.2%, 68.6%); Nigeria, 63.7% (95% CI: 12.7%, 84.9%); and The Gambia,
77.9% (95% CI: 46.6%, 90.8%). As in 2015, in Mali there was no evidence of heterogeneity
between Diema and Sanso districts in the association between malaria and SMC (LRT p =
0.81).
Overall protective effectiveness of SMC against clinical malaria
Overall, a random-effects meta-analysis including all 7 studies gave an estimated pooled OR of
0.12 (95% CI: 0.06, 0.21) for SMC in the previous 28 days, indicating a protective effectiveness
of SMC against clinical malaria of 88% (95% CI: 79%, 94%) (Fig 3). This analysis indicated evi-
dence of heterogeneity (LRT 25.9, 6 d.f., I2 76.8% [95% CI: 51.5%, 88.9%]; p< 0.001) between
studies. When the study from Mali, 2015, which had the highest estimate of protective effec-
tiveness, was removed, there was then weaker evidence of heterogeneity (LRT 12.8, 5 d.f., I2
60.9% [95% CI: 4.4%, 84.0%]; p = 0.025), and a pooled estimate of PE of 85% (95% CI: 76%,
95%). Effectiveness against clinical malaria in the period 29–42 days was 61% (95% CI: 47%,
72%), with no evidence for heterogeneity between studies (LRT 4.77, 6 d.f., I2 0.0% [95% CI:
0.0%, 70.8%]; p = 0.57). The 90% prediction interval (which accounts for between-study vari-
ability) for the OR for SMC within the previous 28 days (i.e., where the effect size might be
expected to lie in a future study) was 0.022 to 0.597, corresponding to a PE of 40.3% to 97.8%.
Fixed-effects meta-analysis gave a similar but slightly lower overall estimate of PE in the
period 0–28 days: 84% (95% CI: 79%, 88%) (Fig B in S1 Fig). Use of fixed-effects meta-analysis
did not change the estimated PE in the period 29–42 days: 61% (95% CI: 47%, 72%).
When the analysis was repeated restricted to matched case–control sets in which the case
had parasite density above 5,000 per microlitre (and excluding Nigeria, 2016, where density
was not estimated), the pooled OR was 0.10 (95% CI: 0.04, 0.21) for SMC in the previous 28
days, indicating a protective effectiveness of SMC against clinical malaria with high parasite
density of 90% (95% CI: 79%, 96%), and 0.41 (95% CI: 0.26, 0.66) for SMC 29–42 days ago,
indicating a protective effectiveness of 59% (95% CI: 34%, 74%) (Fig C in S1 Fig).
Protective effectiveness of LLIN use against clinical malaria
Compared to SMC, there were fewer case–control pairs that were discordant for LLIN use,
and consequently wide uncertainty in LLIN protective effectiveness in most studies (Tables F
to L in S1 Tables for individual countries, summarised in Table M in S1 Tables). Protective
effectiveness of LLIN use was demonstrated in The Gambia, 2015 (49.9% [95% CI: 19.1%,
69.0%]), and Nigeria, 2016 (75.1% [95% CI: 62.2%, 83.6%]).
Discussion
Our results suggest that SMC provided a very high degree of personal protection against clini-
cal malaria for the first 28 days after each treatment. Protection was then lower in the period
29–42 days after treatment, emphasising the importance of repeating treatments at monthly
intervals. This finding was consistent across the different studies, which took place in locations
representing a range of transmission intensity and seasonality patterns within the wider SMC
area.
These results showing high protective effectiveness against clinical malaria are consistent
with the results of previous clinical trials showing high protection from SMC [1], with reported
good adherence to the 3-day SMC regimen (in this study and in the SMC coverage surveys
conducted during ACCESS-SMC), and with the low frequency of molecular markers of resis-
tance to SMC drugs observed in the implementing countries in West Africa [4]. It is reassuring
that the profile of protection over time agrees well with that estimated from previous studies
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Fig 3. Meta-analysis of the odds ratio for seasonal malaria chemoprevention (SMC) within the previous 28 days
and 29–42 days ago. (a) SMC within the previous 28 days; (b) SMC 29–42 days ago. Results from random-effects
meta-analysis.
https://doi.org/10.1371/journal.pmed.1003727.g003
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[17], and that consistent results were obtained with the more specific case definition of P. fal-
ciparum density of more than 5,000 per microlitre, for which malaria is more likely to be the
true cause of fever. In large clinical trials of SP plus AQ for SMC [18,19], protective effective-
ness against clinical malaria over the transmission season was 70% in Burkina Faso and 82% in
Mali. These estimates are not directly comparable with estimates from the current case–con-
trol study as they included person-time at risk up to 6 weeks after the final SMC treatment,
and included children who either missed SMC courses or had malaria at the time of SMC and
received artemether–lumefantrine instead of SP plus AQ. The efficacy over 28 days in these tri-
als was 83% [20], comparable to the effectiveness estimate in this study.
In this study, a child was considered to have received SMC if the first dose was administered
by a community health worker, regardless of adherence to subsequent doses or vomiting of the
medication. The high estimated effectiveness of SMC suggests that any failure to complete the
3-day regimen that may have occurred did not markedly reduce effectiveness.
It is challenging to measure adherence to the 3-day SMC regimen under routine conditions.
Most caregivers reported that they completed the 3-day treatment course in this study, as was
reported during coverage surveys during ACCESS-SMC [4]. Drug distributors are trained to
repeat the first dose if the child vomits; administrative records suggest this occurs infrequently
(e.g., K. M. Loua and P. Milligan, personal communication). However, it is common for
young children to spit out some of the medication, and it is difficult to determine how much
of the medication was ingested.
Large-scale molecular marker surveys were carried out in nearby areas of each country dur-
ing the ACCESS-SMC project. Although the dhfr-triple mutations and the dhps-437 mutation
(conferring resistance to pyrimethamine and sulphadoxine, respectively) are present in West
Africa, the dhps-540 and dhps-581 mutations (which confer a higher grade resistance to SP)
are very rare, and there is a low prevalence of the mdr and pfcrt mutations thought to confirm
high-grade resistance to AQ [4]. Ongoing monitoring of these molecular markers will be
needed to detect any increase in the prevalence and severity of SP resistance, but changes in
the prevalence of markers alone cannot indicate in vivo efficacy of chemoprevention [5,6].
Case–control studies offer a reasonably quick and inexpensive approach to estimate protective
effectiveness to complement this approach, and can be used to confirm effectiveness even in
situations where impact is difficult to measure or interpret due to weak surveillance or changes
in malaria detection rates or access to treatment.
There are a number of limitations to this study. There could be a potential bias towards
higher estimated effectiveness of SMC against clinical malaria if malaria exposure is greater in
areas with poorer access to SMC; selecting controls from the same neighbourhood attempts to
at least partially control for this. Residual confounding may remain, but the sharp decrease in
effectiveness with time since dose argues against a substantial bias. A potential bias towards
lower estimated effectiveness of SMC is that cases might have better access to care than con-
trols. If the factors that result in better access to care also result in better access to SMC, this
might be associated with higher coverage of SMC among cases, biasing effectiveness down-
wards. Neighbourhood controls attempt to control for key factors affecting access, such as dis-
tance to health centre, but not all factors (e.g., caregivers with more or less time or resources to
take children for treatment when unwell). Test-negative designs, which use patients who test
negative for malaria as controls, would more fully control for access to care, but, in the Sahel
context, where transmission remains high, selecting children without malaria parasitaemia (or
non-febrile children with asymptomatic parasitaemia) would be likely to selectively include
SMC recipients as controls. This would bias estimated effectiveness upwards, and thus neigh-
bourhood controls were preferred.
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Controls were more likely to be female than cases, and slightly older on average. However,
adjustment for these factors suggests that this did not introduce important confounding. Chil-
dren from households with a large number of other children may be under-represented in the
controls, because control households were chosen first, then a single child within the house-
hold selected [21]. This could create an artefactual association between household size and
malaria. However, household size did not appear to be associated with receipt of SMC, and
controlling for household size did not change estimates of the association between malaria and
SMC in any of the studies.
Previous exposure to SMC was documented based on the SMC card, where this was avail-
able, and otherwise according to caregiver recall, checked carefully against distribution dates
for the community. Although there is the potential for this to introduce recall bias, provided
controls are recruited at or soon after the time that the case is recruited, the length of the recall
period is relatively short. Detailed coverage surveys carried out in other areas implementing
SMC found reasonably high retention of the SMC distribution card, and good agreement
between SMC card and recall within the same malaria transmission season [4].
Estimates of protection against clinical malaria within the first 28 days after SMC are likely
to be sensitive to the exact timing of recruitment with respect to the previous SMC cycle. For
example, the exposure status of cases could differ between the first week following SMC (when
one would expect very few cases to have previously received SMC) and the final week of each
monthly cycle (when more cases may have received SMC at the time of the last cycle, but still
become unwell in spite of this). In 2016, we attempted to standardise this by recruiting a con-
stant number of cases in each week of the study, over the whole season. In 2015, recruitment
began towards the end of the malaria transmission season, and limiting the number of cases
recruited in this way was not possible due to the declining malaria burden. This may explain
the high efficacy estimate in Mali, in 2015, as many of the discordant case–control sets were
recruited very soon after SMC (Fig A in S1 Fig), when the SP and AQ were likely to have very
high efficacy.
Despite these limitations, the close agreement between the effectiveness estimates obtained
in different locations within the SMC area, and in countries where different levels of SMC cov-
erage were achieved (very high in Burkina Faso, and much lower in Nigeria and Chad [4]), is
reassuring. Case–control studies have been widely used to evaluate preventive interventions
such as vaccines [10], and other preventive interventions for malaria [12]. Use of case–control
studies for the evaluation of SMC is more complicated than for interventions such as vaccines
because (1) the expected duration of protection is short, even if SMC is working well, and (2)
there are multiple SMC cycles within a short period of time. Both these factors mean that accu-
rate documentation of the date of receipt of SMC is critical in a way that would not be the case
for a vaccine providing lifelong immunity (for which prior receipt of the vaccine or not, as a
binary outcome, may be sufficient, without reference to specific dates). Despite these chal-
lenges, our results suggest that this approach is a valid method to monitor the effectiveness of
SMC in vivo, complementing other approaches, and potentially providing an approach to
monitor the effect of SMC on severe malaria, which is difficult to do using prospective
approaches. This approach also allows the effect of other risk factors to be estimated, including
the protection from other interventions. We attempted to do this for LLINs in this study, but
the high coverage of LLINs affected precision in some study centres.
Case–control studies require close attention to methodology, including quality-controlled
microscopy at the point of recruitment and careful design, supervision, and analysis, and
should to be undertaken by suitably trained teams. It is important to collect a full SMC history
from all cases and controls, including SMC in previous months, and to measure potential con-
founders carefully. However, if these challenges can be met, the design can give meaningful
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results even when implemented in only a small number of health facilities, and the costs are
relatively low, even with the need to travel to conduct home visits.
In areas where case–control studies are planned, there should be a particular effort to docu-
ment SMC dates carefully, both on the SMC card and in SMC registers, and to record accu-
rately the dates of SMC campaigns in the study area and the dates of any call back visits made
by the delivery teams after the main distribution dates. In some countries implementing SMC
(e.g., The Gambia), children have an ID card with a quick response (QR) code, permitting elec-
tronic data capture of SMC delivery, permitting more accurate ascertainment of treatment
dates.
If carried out properly, case–control studies can be a powerful tool to monitor SMC effec-
tiveness, and these studies should be repeated at regular intervals and in a range of locations.
These studies could also be done reactively in response to concerns about low effectiveness
(e.g., many children reporting malaria despite receipt of SMC) or apparent low impact (e.g., a
particularly high burden in routine health system data). This is important because alarm about
loss of effectiveness may arise from fluctuations in malaria incidence over time (leading to
peaks in malaria cases that suggest loss of protection) and/or from the observation that a high
percentage of malaria cases have recently received SMC (which would be expected if coverage
is high) [22].
These results from 5 countries confirm that SMC as used in routine programmes provides a
high degree of personal protection against clinical malaria, consistent with reported adherence
and low frequencies of molecular markers of resistance, and support the continued deploy-




S1 Fig. Supplementary results Figs A to C, as referred to in the text.
(DOCX)
S1 Methods. Sample size for the case–control studies.
(DOCX)
S1 Tables. Supplementary results Tables A to M, as referred to in the text.
(DOCX)
Acknowledgments
ACCESS-SMC was a project led by Malaria Consortium in partnership with Catholic Relief
Services, and in collaboration with the London School of Hygiene & Tropical Medicine, Man-
agement Sciences for Health, Medicines for Malaria Venture, and Speak Up Africa. ACCESS-
SMC supported national malaria control programmes to expand access to SMC to save chil-
dren’s lives across 7 countries in the Sahel (Burkina Faso, Chad, Guinea, Mali, Niger, Nigeria,
and The Gambia). The authors thank the lab technicians, nurses, field workers, and supervi-
sors for data collection, and all the caregivers, parents, and children for their participation. We
acknowledge the important contributions of the following individuals to the conduct of the
case–control studies: Amulai Touray, Olimatou Kolley, Anthony Mendy, Abdoulie Camara,
and Kebba Naban in The Gambia, and Drs. Hamma Maiga, Mahamadou Kaya, and Seydou
Traore in Mali.
PLOS MEDICINE Case-control studies to evaluate seasonal malaria chemoprevention at scale
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003727 September 8, 2021 16 / 19
Corinne Merle is a staff member of the World Health Organization (WHO); the authors
alone are responsible for the views expressed in this publication, and they do not necessarily
represent the decisions, policy, or views of the WHO.
Author Contributions
Conceptualization: Matthew Cairns, Paul Milligan.
Data curation: Matthew Cairns, Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kes-
sely, Kadidja Gamougam, Johnbull Sonny Ogboi, Tony Eloike, Paul Snell, Susana Scott,
Kalifa Bojang, Jean Bosco Ouedraogo, Alassane Dicko.
Formal analysis: Matthew Cairns, Paul Milligan.
Funding acquisition: Paul Milligan.
Investigation: Matthew Cairns, Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kes-
sely, Kadidja Gamougam, Johnbull Sonny Ogboi, Tony Eloike, Jean Bosco Ouedraogo,
Alassane Dicko, Paul Milligan.
Methodology: Matthew Cairns, Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kes-
sely, Kalifa Bojang, Jean Bosco Ouedraogo, Alassane Dicko, Paul Milligan.
Project administration: Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kessely,
Kadidja Gamougam, Abdoulaye Diallo, Diego Moroso, Suzanne Van Hulle, Tony Eloike,
Paul Snell, Susana Scott, Corinne Merle, Kalifa Bojang, Jean Bosco Ouedraogo, Alassane
Dicko, Jean-Louis Ndiaye, Paul Milligan.
Supervision: Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kessely, Kadidja
Gamougam, Abdoulaye Diallo, Johnbull Sonny Ogboi, Diego Moroso, Suzanne Van Hulle,
Tony Eloike, Susana Scott, Kalifa Bojang, Jean Bosco Ouedraogo, Alassane Dicko, Jean-
Louis Ndiaye, Paul Milligan.
Validation: Matthew Cairns, Serign Jawo Ceesay, Issaka Sagara, Issaka Zongo, Hamit Kessely,
Kadidja Gamougam, Johnbull Sonny Ogboi, Tony Eloike, Kalifa Bojang, Jean Bosco Oue-
draogo, Alassane Dicko, Paul Milligan.
Visualization: Matthew Cairns.
Writing – original draft: Matthew Cairns, Paul Milligan.
Writing – review & editing: Matthew Cairns, Serign Jawo Ceesay, Issaka Sagara, Issaka
Zongo, Hamit Kessely, Kadidja Gamougam, Abdoulaye Diallo, Johnbull Sonny Ogboi,
Diego Moroso, Suzanne Van Hulle, Tony Eloike, Paul Snell, Susana Scott, Corinne Merle,
Kalifa Bojang, Jean Bosco Ouedraogo, Alassane Dicko, Jean-Louis Ndiaye, Paul Milligan.
References
1. Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C. Intermittent preventive treatment for
malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev. 2012; 2:
CD003756. https://doi.org/10.1002/14651858.CD003756.pub4 PMID: 22336792
2. World Health Organization. WHO policy recommendation: seasonal malaria chemoprevention (SMC)
for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-
region in Africa. Geneva: World Health Organization; 2012 [cited 2021 Aug 26]. Available from: https://
www.who.int/malaria/mpac/feb2012/smc_policy_recommendation.pdf.
3. London School of Hygiene & Tropical Medicine. OPT-SMC: SMC in 2020. London: London School of
Hygiene & Tropical Medicine; 2021 [cited 2021 Aug 27]. Available from: https://www.lshtm.ac.uk/
research/centres-projects-groups/opt-smc#smc-in-2020.
PLOS MEDICINE Case-control studies to evaluate seasonal malaria chemoprevention at scale
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003727 September 8, 2021 17 / 19
4. Partnership ACCESS-SMC. Effectiveness of seasonal malaria chemoprevention at scale in west and
central Africa: an observational study. Lancet. 2020; 396(10265):1829–40. https://doi.org/10.1016/
S0140-6736(20)32227-3 PMID: 33278936
5. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, et al. Protective efficacy of inter-
mittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite
resistance. PLoS ONE. 2010; 5(9):e12618. https://doi.org/10.1371/journal.pone.0012618 PMID:
20838642
6. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of sulfadoxine-
pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy
at clearing infections and preventing low birth weight. Clin Infect Dis. 2016; 62(3):323–33. https://doi.
org/10.1093/cid/civ881 PMID: 26486699
7. Diawara F, Steinhardt LC, Mahamar A, Traore T, Kone DT, Diawara H, et al. Measuring the impact of
seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. Malar J. 2017; 16
(1):325. https://doi.org/10.1186/s12936-017-1974-x PMID: 28797263
8. Druetz T, Corneau-Tremblay N, Millogo T, Kouanda S, Ly A, Bicaba A, et al. Impact evaluation of sea-
sonal malaria chemoprevention under routine program implementation: a quasi-experimental study in
Burkina Faso. Am J Trop Med Hyg. 2018; 98(2):524–33. https://doi.org/10.4269/ajtmh.17-0599 PMID:
29260654
9. Maiga H, Gaudart J, Sagara I, Diarra M, Bamadio A, Djimde M, et al. Two-year scale-up of seasonal
malaria chemoprevention reduced malaria morbidity among children in the health district of Koutiala,
Mali. Int J Environ Res Public Health. 2020; 17(18):6639. https://doi.org/10.3390/ijerph17186639 PMID:
32932990
10. Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, et al. Case-control vaccine effective-
ness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017; 35(25):3295–
302. https://doi.org/10.1016/j.vaccine.2017.04.037 PMID: 28442231
11. Alexander N, Rodriguez M, Perez L, Caicedo JC, Cruz J, Prieto G, et al. Case-control study of mosquito
nets against malaria in the Amazon region of Colombia. Am J Trop Med Hyg. 2005; 73(1):140–8. PMID:
16014849
12. D’Alessandro U, Olaleye B, Langerock P, Bennett S, Cham K, Cham B, et al. The Gambian National
Impregnated Bed Net Programme: evaluation of effectiveness by means of case-control studies. Trans
R Soc Trop Med Hyg. 1997; 91(6):638–42. https://doi.org/10.1016/s0035-9203(97)90502-2 PMID:
9509168
13. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. Am J
Epidemiol. 1982; 116(3):547–53. https://doi.org/10.1093/oxfordjournals.aje.a113439 PMID: 7124721
14. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the
demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol.
1990; 19(1):205–13. https://doi.org/10.1093/ije/19.1.205 PMID: 2190942
15. Dalrymple U, Arambepola R, Gething PW, Cameron E. How long do rapid diagnostic tests remain posi-
tive after anti-malarial treatment? Malar J. 2018; 17(1):228. https://doi.org/10.1186/s12936-018-2371-9
PMID: 29884184
16. Kish L. A procedure for objective respondent selection within the household. J Am Stat Assoc. 1949;
44:380–7.
17. Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, et al. Randomized noninferiority
trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for
seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015; 59(8):4387–
96. https://doi.org/10.1128/AAC.04923-14 PMID: 25918149
18. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, et al. Intermittent preventive treatment of
malaria provides substantial protection against malaria in children already protected by an insecticide-
treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011; 8(2):
e1000407. https://doi.org/10.1371/journal.pmed.1000407 PMID: 21304923
19. Konate AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansane A, Soulama I, et al. Intermittent preventive
treatment of malaria provides substantial protection against malaria in children already protected by an
insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS
Med. 2011; 8(2):e1000408. https://doi.org/10.1371/journal.pmed.1000408 PMID: 21304925
20. WHO/GMP Technical expert group on preventive chemotherapy. Report of the Technical consultation
on Seasonal Malaria Chemoprevention (SMC)/Chimio-prévention saisonnière du paludisme (CSP).
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